N
BCAX

Nuveen’s Bicara Therapeutics BCAX Stock Holding History

Nuveen’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$875K Buy
43,984
+5,143
+13% +$88.5K ﹤0.01% 2636
2025
Q4 		$654K Sell
38,841
-5,596
-13% -$95.6K ﹤0.01% 2777
2025
Q3 		$702K Hold
44,437
– – ﹤0.01% 2775
2025
Q2 		$413K Buy
44,437
+19,409
+78% +$231K ﹤0.01% 2944
2025
Q1 		$326K Hold
25,028
– – ﹤0.01% 3016
2024
Q4 		$436K Buy
+25,028
New +$521K ﹤0.01% 3030

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Nuveen's BCAX Position: Q1 2026 in Review

Nuveen increased its Bicara Therapeutics (BCAX) stake by 13% in Q1 2026, buying an estimated $88.5K and bringing the position to 43,984 shares worth $875K. The position accounts for ﹤0.01% of the portfolio, ranked #2636.

Nuveen first reported a position in BCAX in Q4 2024 and has held it in 6 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Nuveen held 43,984 shares of Bicara Therapeutics worth $875K as of Q1 2026.
  • Nuveen bought 5,143 Bicara Therapeutics shares in Q1 2026, an estimated $88.5K.
  • Bicara Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2636 holding.
  • Nuveen first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.